{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Setup"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Import Packages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os, json\n",
    "from langchain.embeddings import OpenAIEmbeddings\n",
    "from langchain.vectorstores import FAISS\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "from langchain.agents.mrkl.base import ZeroShotAgent\n",
    "from langchain.chains import LLMChain\n",
    "\n",
    "from langchain.agents import AgentExecutor, AgentOutputParser, initialize_agent\n",
    "from custom_agents import HumanSearchRetrievalToolkit, RetrievalToolkit, HumanRetrievalToolkit"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Setup Directories"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "MAIN_DIR = \"..\"\n",
    "EMB_DIR = os.path.join(MAIN_DIR, \"data\", \"emb_store\", \"uc\", \"faiss\", \"text-embedding-ada-002\", \"v8-add-tables_2500_500\")\n",
    "\n",
    "with open(os.path.join(MAIN_DIR, \"auth\", \"api_keys.json\"), \"r\") as f:\n",
    "    api_keys = json.load(f)\n",
    "    \n",
    "os.environ[\"OPENAI_API_KEY\"] = api_keys[\"OPENAI_API_KEY\"]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Load Test Cases"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total number of test cases: 30\n"
     ]
    }
   ],
   "source": [
    "with open(os.path.join(MAIN_DIR, \"data\", \"queries\", \"uc_all.txt\"),\n",
    "          \"r\", encoding=\"utf-8-sig\") as f:\n",
    "    test_cases = f.readlines()\n",
    "test_cases = [test_case.rstrip() for test_case in test_cases]\n",
    "\n",
    "print(\"Total number of test cases:\", len(test_cases))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# ReAct and MRKL Agents"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Define Toolkit"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "docsearch = FAISS.load_local(EMB_DIR, OpenAIEmbeddings())\n",
    "llm = ChatOpenAI(model_name=\"gpt-4\", temperature=0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tool number 1: human\n",
      "Tool number 2: google_serper\n",
      "Tool number 3: Docsearch QA Tool\n",
      "Tool number 4: General Knowledge\n"
     ]
    }
   ],
   "source": [
    "toolkit1 = HumanSearchRetrievalToolkit(\n",
    "    serper_api_key=api_keys[\"SERP_API\"],\n",
    "    llm = llm, docsearch=docsearch\n",
    ")\n",
    "\n",
    "tools = toolkit1.get_tools()\n",
    "for idx, tool in enumerate(tools):\n",
    "    print(f\"Tool number {idx+1}: {tool.name}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Define Agent Instructions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "You are a helpful and honest physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
      "If you do not know the answer, you will not make up an answer and instead ask further questions for clarifications\n",
      "\n",
      "Your job is to ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
      "- Whether treated patient is new patient or patient under maintenance\n",
      "- Prior response to Infliximab\n",
      "- Prior failure to Anti-TNF agents\n",
      "- Prior failure to Vedolizumab\n",
      "- Age\n",
      "- Pregnancy\n",
      "- Extraintestinale manifestations\n",
      "- Pouchitis\n",
      "\n",
      "FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\n",
      "\n",
      "You have access to the following tools:\n",
      "\n",
      "human: You can ask a human for guidance when you think you got stuck or you are not sure what to do next. The input should be a question for the human.\n",
      "google_serper: A low-cost Google Search API.Useful for when you need to answer questions about current events.Input should be a search query.\n",
      "Docsearch QA Tool: Use this tool to search for document and answer questions related to treatment of disease\n",
      "General Knowledge: Useful for general knowledge question\n",
      "\n",
      "Use the following format:\n",
      "\n",
      "Question: the input question you must answer\n",
      "Thought: you should always think about what to do\n",
      "Action: the action to take, should be one of [human, google_serper, Docsearch QA Tool, General Knowledge]\n",
      "Action Input: the input to the action\n",
      "Observation: the result of the action\n",
      "... (this Thought/Action/Action Input/Observation can repeat N times)\n",
      "Thought: I now know the final answer\n",
      "Final Answer: the final answer to the original input question\n",
      "\n",
      "Begin!\n",
      "\n",
      "Patient Profile: {input}\n",
      "Thought: {agent_scratchpad}\n"
     ]
    }
   ],
   "source": [
    "PREFIX = \"\"\"You are a helpful and honest physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC).\n",
    "If you do not know the answer, you will not make up an answer and instead ask further questions for clarifications\n",
    "\n",
    "Your job is to ANALYSE the given patient profile based on given query based on one of the following criteria:\n",
    "- Whether treated patient is new patient or patient under maintenance\n",
    "- Prior response to Infliximab\n",
    "- Prior failure to Anti-TNF agents\n",
    "- Prior failure to Vedolizumab\n",
    "- Age\n",
    "- Pregnancy\n",
    "- Extraintestinale manifestations\n",
    "- Pouchitis\n",
    "\n",
    "FINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\n",
    "\n",
    "You have access to the following tools:\"\"\"\n",
    "\n",
    "FORMAT_INSTRUCTIONS = \"\"\"Use the following format:\n",
    "\n",
    "Question: the input question you must answer\n",
    "Thought: you should always think about what to do\n",
    "Action: the action to take, should be one of [{tool_names}]\n",
    "Action Input: the input to the action\n",
    "Observation: the result of the action\n",
    "... (this Thought/Action/Action Input/Observation can repeat N times)\n",
    "Thought: I now know the final answer\n",
    "Final Answer: the final answer to the original input question\"\"\"\n",
    "\n",
    "SUFFIX = \"\"\"Begin!\n",
    "\n",
    "Patient Profile: {input}\n",
    "Thought: {agent_scratchpad}\"\"\"\n",
    "\n",
    "AGENT_PROMPT_1 = ZeroShotAgent.create_prompt(\n",
    "    tools=tools,\n",
    "    prefix=PREFIX,\n",
    "    suffix=SUFFIX,\n",
    "    format_instructions=FORMAT_INSTRUCTIONS,    \n",
    ")\n",
    "\n",
    "print(AGENT_PROMPT_1.template)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Setup Agent and AgentExecutor"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "agent_llm = LLMChain(\n",
    "    llm = ChatOpenAI(model_name = \"gpt-4\", temperature = 0, max_tokens = 512),\n",
    "    prompt = AGENT_PROMPT_1\n",
    ")\n",
    "REACT_AGENT_1 = ZeroShotAgent(llm_chain=agent_llm, allowed_tools = [tool.name for tool in tools])\n",
    "\n",
    "agent_args = {\"max_iterations\": 3, \"early_stopping_method\": \"generate\"}\n",
    "agent_executor = AgentExecutor.from_agent_and_tools(agent=REACT_AGENT_1, tools=tools, verbose=True, **agent_args)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Run Test Case"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[32;1m\u001b[1;3mThe patient is newly diagnosed with moderate UC and has extraintestinal manifestations. I need to consider these factors while suggesting the biological drugs. I will use the Docsearch QA Tool to find the best treatment options for a newly diagnosed patient with these conditions.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: Best biological drugs for newly diagnosed moderate UC with extraintestinal manifestations\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[38;5;200m\u001b[1;3m{'question': 'Best biological drugs for newly diagnosed moderate UC with extraintestinal manifestations', 'answer': \"The best biological drugs for newly diagnosed moderate Ulcerative Colitis (UC) with extraintestinal manifestations are Infliximab, Vedolizumab, and Ustekinumab. Infliximab is ranked highest for induction of clinical remission and endoscopic improvement in biologic-naïve patients. Ustekinumab and Tofacitinib are ranked highest in patients with prior exposure to TNF antagonists. Upadacitinib 45mg o.d. ranked first for clinical remission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed. However, it's important to note that all available drugs, other than Adalimumab 160/160mg, Adalimumab 80/40mg, and Filgotinib 100mg o.d. were more efficacious than placebo for the treatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs were safe and well-tolerated, with no significant increase in serious adverse events or adverse events leading to withdrawal over the rates seen in the placebo arms.\\n\", 'sources': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf, data/document_store/uc/agrawal.pdf, data/document_store/uc/otad009.pdf, data/document_store/uc/PIIS1542356520300446.pdf', 'source_documents': [Document(page_content='Burr et al. \\n \\n8 of 45 \\nIn the last 10 years small molecules, which can be administered orally and on a daily \\nbasis, have also been evaluated in moderate to severe UC. These include janus kinase \\ninhibitors, such as tofacitinib,[20] and the sphingosine-1-phosphate receptor modulator, \\nozanimod.[21] The comparative efficacy and safety of all these drugs has been assessed in \\nprior network meta-analyses.[22, 23] These demonstrated that infliximab was ranked highest \\noverall for efficacy, and ustekinumab and tofacitinib were ranked highest in patients with \\nprevious anti-TNF-α exposure. However, this is a rapidly moving field, and there are already \\nseveral newer drugs that have shown efficacy in phase III clinical trials that were not \\nconsidered in these network meta-analyses.[24-26] We have therefore performed an updated \\nnetwork meta-analysis to evaluate the efficacy of all biological therapies and small molecules \\nthat have progressed on to phase III trials, compared with each other or with placebo, in terms \\nof induction of remission, endoscopic improvement, and clinical response, as well as safety, \\nin patients with moderate to severely active UC.', metadata={'source': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'file_path': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'page': 8, 'total_pages': 46, 'format': 'PDF 1.7', 'title': 'Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis', 'author': 'Burr, NE, Gracie, DJ, Black, CJ and Ford, AC', 'subject': '', 'keywords': 'meta-analysis; ulcerative colitis', 'creator': 'Microsoft® Word for Microsoft 365', 'producer': 'GPL Ghostscript 9.25', 'creationDate': \"D:20230106151148Z00'00'\", 'modDate': \"D:20230106151148Z00'00'\", 'trapped': '', 'modal': 'text'}), Document(page_content='Burr et al. \\n \\n29 of 45 \\npreferential janus kinase-1 inhibitor, although given filgotinib also has increased selectivity \\nfor janus kinase-1 this cannot be the sole reason for upadacitinib’s higher ranking. Despite \\nthese limitations, the results of our study are still useful for informing treatment decisions for \\npatients with moderate to severely active UC and can be used in future updates of evidence-\\nbased management guidelines.  \\nAn initial network meta-analyses by Singh et al. demonstrated infliximab to be the \\nmost efficacious drug for patients naïve to biological therapies in terms of induction of \\nclinical remission and endoscopic improvement, with vedolizumab ranked second.[22] In \\npatients exposed to biological therapies tofacitinib ranked first for both clinical remission and \\nendoscopic improvement. An update to this work from 2020, including data from head-to-\\nhead trials of vedolizumab and adalimumab, as well as phase III placebo-controlled trials of \\nustekinumab, demonstrated again that infliximab was ranked first for induction of clinical \\nremission and endoscopic improvement in biologic-naïve patients, with ustekinumab and \\ntofacitinib ranked highest in patients previously exposed to biologics.[23] This later network \\nmeta-analysis included 14 induction of remission trials, recruiting almost 5500 patients, \\nalthough the Japanese trial of infliximab versus placebo in 208 patients reported by \\nKobayashi et al. was not included.[42] In contrast to these previous network meta-analyses, \\nour results provide hope that some novel drugs, which are likely to come to market soon, are \\npotentially more efficacious for moderate to severely active UC than existing licensed \\ntherapies. \\nOur results confirm that all available drugs, other than adalimumab 160/160mg, \\nadalimumab 80/40mg, and filgotinib 100mg o.d. were more efficacious than placebo for the \\ntreatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs \\nwere safe and well-tolerated, with no significant increase in serious adverse events or adverse \\nevents leading to withdrawal over the rates seen in the placebo arms, although the RR of', metadata={'source': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'file_path': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'page': 29, 'total_pages': 46, 'format': 'PDF 1.7', 'title': 'Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis', 'author': 'Burr, NE, Gracie, DJ, Black, CJ and Ford, AC', 'subject': '', 'keywords': 'meta-analysis; ulcerative colitis', 'creator': 'Microsoft® Word for Microsoft 365', 'producer': 'GPL Ghostscript 9.25', 'creationDate': \"D:20230106151148Z00'00'\", 'modDate': \"D:20230106151148Z00'00'\", 'trapped': '', 'modal': 'text'}), Document(page_content='Burr et al. \\n \\n5 of 45 \\nSTUDY HIGHLIGHTS \\n \\nWhat is already known about this subject \\n• Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \\nflares of disease activity, some of which may be moderate to severe. \\n• These are usually treated with corticosteroids, which have potentially serious adverse \\neffects, so biological therapies and small molecules have been developed and licensed \\nfor this indication.  \\n• Although previous network meta-analyses have compared their efficacy and safety, \\nthis is a rapidly moving field, and there are already several newer drugs that have \\nshown efficacy in phase III clinical trials that were not considered in these. \\n \\nWhat are the new findings \\n• In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \\nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \\n(TNF)-α therapies, and in patients naïve to these drugs.  \\n• In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \\nupadacitinib 45mg o.d., and infliximab 5mg/kg.  \\n• However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \\npatients previously exposed to anti-TNF-α therapies, and in patients who were anti-\\nTNF-α naïve.  \\n• None of the drugs studied were more likely to lead to serious adverse events than \\nplacebo.', metadata={'source': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'file_path': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'page': 5, 'total_pages': 46, 'format': 'PDF 1.7', 'title': 'Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis', 'author': 'Burr, NE, Gracie, DJ, Black, CJ and Ford, AC', 'subject': '', 'keywords': 'meta-analysis; ulcerative colitis', 'creator': 'Microsoft® Word for Microsoft 365', 'producer': 'GPL Ghostscript 9.25', 'creationDate': \"D:20230106151148Z00'00'\", 'modDate': \"D:20230106151148Z00'00'\", 'trapped': '', 'modal': 'text'}), Document(page_content='Burr et al. \\n \\n27 of 45 \\nDISCUSSION \\nWe conducted a contemporaneous systematic review and network meta-analysis of \\nbiological therapies and small molecules for moderate to severely active UC. This has \\nincorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \\nremission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \\npatients, in patients previously exposed to anti-TNF-α therapies, and in patients naïve to these \\ndrugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \\nupadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \\nranked first in patients previously exposed to anti-TNF-α therapies, and in patients who were \\nanti-TNF-α naïve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \\nadverse events, and ustekinumab 130mg first. However, none of the drugs studied were more \\nlikely to lead to serious adverse events than placebo, although etrolizumab 105mg was more \\nlikely to lead to serious adverse events than golimumab 200/100mg, ustekinumab 6mg/kg, \\nvedolizumab 300mg, and infliximab 5mg/kg. Vedolizumab 300mg was the least likely drug \\nto lead to infections. Infections were significantly more likely with tofacitinib 10mg b.i.d. \\nthan with either placebo or vedolizumab 300mg. Finally, withdrawals due to adverse events \\nwere significantly less likely with upadacitinib 45mg o.d. than with placebo. Upadacitinib \\n45mg o.d. was significantly less likely to lead to withdrawals due to an adverse event than \\ninfliximab 5mg/kg and 10mg/kg, vedolizumab 300mg, adalimumab 160/80mg or 80/40mg, \\nfilgotinib 200mg o.d., and etrolizumab 105mg. Applying GRADE criteria to our estimates of \\neffects, certainty in the quality of evidence would be high.  \\nThere are some limitations. Only nine of 27 trials were at low risk of bias across all \\ndomains. Given the timespan of included studies, there is the possibility that trials of newer \\ndrugs included patients with refractory UC who had failed multiple other therapies. However, \\nsome of these more recent trials only recruited patients who were naïve to anti-TNF-α', metadata={'source': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'file_path': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'page': 27, 'total_pages': 46, 'format': 'PDF 1.7', 'title': 'Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis', 'author': 'Burr, NE, Gracie, DJ, Black, CJ and Ford, AC', 'subject': '', 'keywords': 'meta-analysis; ulcerative colitis', 'creator': 'Microsoft® Word for Microsoft 365', 'producer': 'GPL Ghostscript 9.25', 'creationDate': \"D:20230106151148Z00'00'\", 'modDate': \"D:20230106151148Z00'00'\", 'trapped': '', 'modal': 'text'}), Document(page_content='micronutrients in diet, as well as food additives, processing,\\nand packaging.104 Currently, there is no recommendation\\nfor whole foods–based management of IBD, but future\\nstudies will delineate this further.\\nEarly Therapy of Ulcerative Colitis\\nIn UC, mild disease can be managed with oral and/or\\ntopical mesalamine therapy, generally with adequate con-\\ntrol of disease.38 For moderate UC, VDZ and UST are effec-\\ntive options,105,106 and may be better ﬁrst-choice options\\nthan TNFi, given safety proﬁle. In the VARSITY trial, the only\\nhead-to-head trial of 2 biologics (n ¼ 769), VDZ was supe-\\nrior to ADA in achieving clinical remission (31.3% vs 22.5%;\\nP ¼ .006) and endoscopic improvement (39.7% vs 27.7%; P\\n< .001) in moderate to severe UC.105 In case VDZ or UST\\nmay not be feasible due to payer preference, TNFi, partic-\\nularly IFX, is an effective option with good safety proﬁle.107\\nThiopurines may be considered in moderate UC after\\nweighing risks against beneﬁts.64 In patients with severe UC\\nrequiring hospitalization, IFX is the preferred biologic for\\ninduction and maintenance of remission, with or without\\nIMM. Combination therapy in the SUCCESS trial was asso-\\nciated with improved clinical, but not endoscopic, outcomes\\ncompared to IFX monotherapy.108 When using IFX as a\\nmonotherapy in moderate to severe UC, given the potential\\nfor the colon to act as a “sink” for drugs, we advocate for\\nchecking early drug concentrations to ensure proper dosing\\nand detecting immunogenicity early along with other\\npharmacokinetic and safety-related variables.109 There is no\\nclear beneﬁt of concomitant mesalamine with biologic\\ntherapy in UC and it can be stopped in patients escalating to\\nbiologics.110 Some patients may present with acute severe\\nUC\\nwhere\\nTNFi,\\ncyclosporine,\\nor\\nsubtotal\\ncolectomy\\nfollowed by ileal pouch anal anastomosis can be a good\\ninitial strategy; discussion of management of acute severe\\nUC is beyond the scope of this article.\\nTaking Extraintestinal Manifestation Into\\nConsideration\\nEIMs are common in IBD, estimated to affect 30%–40% of\\npatients.111,112 In a Swiss cohort study, symptoms of EIMs\\nbefore IBD in one-quarter of the patients113; collaboration\\nacross specialties, including but not limited to rheumatolo-\\ngists, dermatologists, ophthalmologists, is vital not only to\\nprompt referral of patients with EIM suspicious for IBD to\\nallow for expedient initiation of therapy for both conditions,\\nbut also to allow for consideration of both in the selection of', metadata={'source': 'data/document_store/uc/agrawal.pdf', 'file_path': 'data/document_store/uc/agrawal.pdf', 'page': 8, 'total_pages': 19, 'format': 'PDF 1.7', 'title': \"Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists\", 'author': 'Manasi Agrawal', 'subject': 'Gastroenterology, 161 (2021) 47-65. doi:10.1053/j.gastro.2021.04.063', 'keywords': '', 'creator': 'Elsevier', 'producer': 'Acrobat Distiller 8.1.0 (Windows)', 'creationDate': \"D:20210619033246+05'30'\", 'modDate': \"D:20210619033336+05'30'\", 'trapped': '', 'modal': 'text'}), Document(page_content='Burr et al. \\n \\n3 of 45 \\nABSTRACT \\nObjective: Biological therapies and small molecules continue to be evaluated in moderate to \\nseverely active ulcerative colitis, but are often studied in placebo-controlled trials, meaning \\ntheir relative efficacy and safety is unknown. We examined this in a network meta-analysis.  \\nDesign: We searched the literature to October 2021 to identify eligible trials. We judged \\nefficacy using clinical remission, endoscopic improvement, or clinical response, and \\naccording to previous exposure or non-exposure to anti-tumour necrosis factor (TNF)-α \\ntherapy. We also assessed safety. We used a random effects model and reported data as \\npooled relative risks (RRs) with 95% confidence intervals (CIs). Interventions were ranked \\naccording to their P-score. \\nResults: We identified 28 trials (12,504 patients). Based on failure to achieve clinical \\nremission, upadacitinib 45mg o.d. ranked first versus placebo (RR = 0.73; 95% CI 0.68-0.80, \\nP-score 0.98), with infliximab 5mg/kg and 10mg/kg second and third, respectively. \\nUpadacitinib ranked first for clinical remission in both patients naïve to anti-TNF-α drugs \\n(RR = 0.69; 95% CI 0.61-0.78, P-score 0.99) and previously exposed (RR = 0.78; 95% CI \\n0.72-0.85, P-score 0.99). Upadacitinib was superior to almost all other drugs in these \\nanalyses. Based on failure to achieve endoscopic improvement infliximab 10mg/kg ranked \\nfirst (RR = 0.61; 95% CI 0.51-0.72, P-score 0.97), with upadacitinib 45mg o.d. second, and \\ninfliximab 5mg/kg third. Upadacitinib was more likely to lead to adverse events, but serious \\nadverse events were no more frequent, and withdrawals due to adverse events were \\nsignificantly lower than with placebo. Infections were significantly more likely with \\ntofacitinib than placebo (RR = 1.41; 95% CI 1.03-1.91). \\nConclusion: In a network meta-analysis, upadacitinib 45mg o.d. ranked first for clinical \\nremission in all patients, patients naïve to anti-TNF-α drugs, and patients previously exposed.', metadata={'source': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'file_path': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'page': 3, 'total_pages': 46, 'format': 'PDF 1.7', 'title': 'Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis', 'author': 'Burr, NE, Gracie, DJ, Black, CJ and Ford, AC', 'subject': '', 'keywords': 'meta-analysis; ulcerative colitis', 'creator': 'Microsoft® Word for Microsoft 365', 'producer': 'GPL Ghostscript 9.25', 'creationDate': \"D:20230106151148Z00'00'\", 'modDate': \"D:20230106151148Z00'00'\", 'trapped': '', 'modal': 'text'}), Document(page_content='2\\nEfficacy and Safety of Advanced Therapies\\nincidence ranges from 9 to 20 cases per 100 000 per year with \\nhigher incidence in North America and Northern Europe.1\\nThe advanced therapeutic armamentarium for adults \\nwith moderately to severely active UC is rapidly evolving. \\nFor over 20 years, biologics targeting specific inflamma-\\ntory pathways have been the mainstay, beginning with those \\ntargeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \\nadalimumab [ADA], and golimumab [GOL]) followed by \\nbiologics with other modes of action (eg, vedolizumab [VED] \\nand ustekinumab [UST]). However, treatment limitations for \\nmoderately to severely active UC remain, including primary \\nnonresponse, secondary loss of response, immunogenicity, and \\nparenteral administration.2 To overcome these limitations, \\nthere has been increasing interest in small molecule drugs \\n(SMDs), which can be orally administered and lack immu-\\nnogenicity.3 Of particular interest are SMDs that inhibit the \\nJanus kinase (JAK)-mediated inflammatory pathway, of which \\ntofacitinib (TOF), filgotinib (FIL), and upadacitinib (UPA) are \\ncurrently approved for use in adults with moderately to se-\\nverely active UC who have had an inadequate response or in-\\ntolerance to conventional therapy and/or TNFi’s.4–7 All orally \\nadministered, TOF, FIL, and UPA are distinguished by their \\nJAK selectivity: TOF is a pan-JAK inhibitor while FIL and \\nUPA are approximately 30- and 60-fold selective for JAK1 \\nover JAK2, respectively.8,9 In human cellular assays, UPA pref-\\nerentially inhibits signaling by JAK1 or JAK1/3 with func-\\ntional selectivity over cytokine receptors that signal via pairs \\nof JAK2.5 In addition, ozanimod (OZA), a SMD that selec-\\ntively modulates the sphingosine-1-phosphase receptor (S1P), \\nis also approved for use in UC.10\\nWith this rapid innovation, much attention has been paid \\ntoward establishing the comparative efficacy and safety of \\nbiologics and SMDs that are approved or in late stages of \\ndevelopment for moderately to severely active UC. Most \\nrecently, Lasa et al11 and Burr et al12 each conducted and \\npublished a systematic literature review (SLR) and frequentist \\nnetwork meta-analysis (NMA) on the efficacy and safety of \\nbiologics and SMDs for patients with moderately to severely \\nUC. Both studies assessed all outcomes after induction (6–14 \\nweeks); Lasa et al11 additionally assessed efficacy after main-\\ntenance (26–66 weeks) separately for treat-through (TT) and', metadata={'source': 'data/document_store/uc/otad009.pdf', 'file_path': 'data/document_store/uc/otad009.pdf', 'page': 1, 'total_pages': 17, 'format': 'PDF 1.4', 'title': '', 'author': '', 'subject': '', 'keywords': '', 'creator': 'Adobe InDesign 15.1 (Windows)', 'producer': 'Adobe PDF Library 15.0; modified using iTextSharp 4.1.6 by 1T3XT', 'creationDate': \"D:20230328133539+05'30'\", 'modDate': \"D:20230523091651+00'00'\", 'trapped': '', 'modal': 'text'}), Document(page_content='What You Need to Know\\nBackground\\nA systematic review and network meta-analysis is\\nneeded to compare efﬁcacy and safety of ﬁrst-line\\n(biologic-naïve) and second-line (prior exposure to\\ntumor necrosis factor [TNF] antagonists) agents for\\ntreatment of moderate to severely active ulcerative\\ncolitis.\\nFindings\\nInﬂiximab was ranked highest in biologic-naïve pa-\\ntients, and ustekinumab and tofacitinib were ranked\\nhighest in patients with prior exposure to TNF an-\\ntagonists, for induction of remission and endoscopic\\nimprovement. More trials of direct comparisons are\\nneeded to inform clinical decision-making with\\ngreater conﬁdence.\\nImplications for patient care\\nPatients with moderate to severely active ulcerative\\ncolitis should receive inﬂiximab or vedolizumab as\\nﬁrst-line therapy, or ustekinumab or tofacitinib if\\nthey have prior exposure to TNF antagonists.\\n2180 Singh et al\\nClinical Gastroenterology and Hepatology Vol. 18, No. 10', metadata={'source': 'data/document_store/uc/PIIS1542356520300446.pdf', 'file_path': 'data/document_store/uc/PIIS1542356520300446.pdf', 'page': 1, 'total_pages': 19, 'format': 'PDF 1.7', 'title': 'First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis', 'author': 'Siddharth Singh', 'subject': 'Clinical Gastroenterology and Hepatology, 18 (2020) 2179-2197. doi:10.1016/j.cgh.2020.01.008', 'keywords': '', 'creator': 'Elsevier', 'producer': 'Acrobat Distiller 8.1.0 (Windows)', 'creationDate': \"D:20200816062640+05'30'\", 'modDate': \"D:20200816062734+05'30'\", 'trapped': '', 'modal': 'text'})]}\u001b[0m\n",
      "Thought:\u001b[32;1m\u001b[1;3mBased on the information from the Docsearch QA Tool, the top two choices of biological drugs for a newly diagnosed patient with moderate UC and extraintestinal manifestations are Infliximab and Vedolizumab. \n",
      "\n",
      "Infliximab is ranked highest for induction of clinical remission and endoscopic improvement in biologic-naïve patients. However, I need to consider the pros and cons of these drugs before suggesting them to the patient. I will use the Docsearch QA Tool to find the pros and cons of Infliximab and Vedolizumab.\n",
      "Action: Docsearch QA Tool\n",
      "Action Input: Pros and cons of Infliximab and Vedolizumab for treatment of moderate UC with extraintestinal manifestations.\u001b[0m\n",
      "\n",
      "\u001b[1m> Entering new RetrievalQAWithSourcesChain chain...\u001b[0m\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "Observation: \u001b[38;5;200m\u001b[1;3m{'question': 'Pros and cons of Infliximab and Vedolizumab for treatment of moderate UC with extraintestinal manifestations.', 'answer': \"Infliximab and Vedolizumab are both used for the treatment of moderate Ulcerative Colitis (UC). Infliximab has been shown to have a higher rate of steroid-free clinical remission and endoscopic remission compared to other treatments in UC patients. It is also considered the most effective for induction in biologic-naïve patients with moderate to severely active Crohn's Disease (CD) (\", 'sources': 'data/document_store/uc/juillerat 2022.pdf, data/document_store/uc/PIIS1542356520300446.pdf). \\n\\nVedolizumab, on the other hand, has been shown to have a more persistent clinical response and steroid-free remission at one year in UC patients compared to anti-TNF agents (SOURCE: data/document_store/uc/juillerat 2022.pdf). However, an increased incidence of extraintestinal manifestations has been observed in vedolizumab-treated IBD patients compared to anti-TNF agents (SOURCE: data/document_store/uc/juillerat 2022.pdf). \\n\\nIn terms of extraintestinal manifestations, Infliximab has shown good efficacy in several cases of pyoderma gangrenosum, a dermatological extraintestinal manifestation. Ustekinumab, another drug, has also shown limited role in this indication, as this drug is also indicated in rheumatoid arthritis (SOURCE: data/document_store/uc/juillerat 2022.pdf). \\n\\nIn conclusion, both Infliximab and Vedolizumab have their pros and cons in the treatment of moderate UC with extraintestinal manifestations. The choice between the two would depend on the specific circumstances and needs of the patient.', 'source_documents': [Document(page_content=\"trial programs compared inﬂiximab with the newcomer ustekinumab\\n(Narula et al., 2021a). This suggested a similar efﬁcacy of the two\\ncompounds as ﬁrst line biological agents in CD patients. The same\\nanalysis was conducted in naïve UC patients, which showed that inﬂix-\\nimab and had similar efﬁcacy based on clinical response, but a signiﬁcant\\nhigher rate of steroid free clinical remission (30% vs. 15%) and endo-\\nscopic remission (36% vs. 26%) was achieved in inﬂiximab treated pa-\\ntients (Narula et al., 2021b). The Sicilian Network for IBD reported\\nsimilar efﬁcacy for adalimumab and vedolizumab in CD patients in a\\npropensity score matched analysis of a cohort conducted between 2016\\nand 2019 (Macaluso et al., 2021), but superiority of vedolizumab in UC\\npatients (Macaluso et al., 2020). Finally, a propensity score matched\\nanalysis of a cohort conducted in Germany (the VEDO IBD study from\\nKompetenznetz Darmerkrankungen) has been presented at the recent\\nECCO congress 2022 comparing vedolizumab and anti-TNF agents in UC\\npatients. This work conﬁrmed a more persistent clinical response (61.7%\\nvs. 40.3%; OR 2.39 (95% CI 1.39–4.10)) and steroid-free remission\\n(36.5% vs. 24.0%; OR 1.82 (95% CI 1.00–3.34)) at one year under\\nvedolizumab (Plachta-Danielzik et al., 2022).\\n2.4. Available data on treatment sequences in algorithms and guidelines\\nData from the literature on strategies to position biological therapy is\\nscarce. Guidance and consensus statements exist to help aid the decision\\nmaking process. However there is a tendency to position all biologics on\\nthe same level and to consider them as interchangeable in the ECCO\\nGuidelines (Torres et al., 2020; Raine et al., 2021). These guidelines, used\\nthe novel Grade methodology which prioritizes meta-analyses (or\\nperform their own) to extract the necessary data to answer speciﬁc (so\\ncall PICO) questions on IBD management (e.g. for anti-TNF agents in UC)\\n(Raine et al., 2021)).\\nIn the most recent publication from the American Gastroenterology\\nAssociation: “Technical Review, the Medical Management of Moderate to\\nSevere Luminal and Perianal Fistulizing Crohn's Disease”, the question of\\ncomparing the efﬁcacy between all available biologics is addressed\\n(Singh et al., 2021). The conclusion was that in biologic-naïve patients\\nwith moderate to severely active CD, inﬂiximab, adalimumab, and\\nustekinumab are the most effective compared to vedolizumab and cer-\\ntolizumab pegol. Inﬂiximab was considered the strongest for induction.\", metadata={'source': 'data/document_store/uc/juillerat 2022.pdf', 'file_path': 'data/document_store/uc/juillerat 2022.pdf', 'page': 2, 'total_pages': 9, 'format': 'PDF 1.7', 'title': 'Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?', 'author': 'Pascal Juillerat', 'subject': 'Current Research in Pharmacology and Drug Discovery, 3 (2022) 100104. doi:10.1016/j.crphar.2022.100104', 'keywords': '', 'creator': 'Elsevier', 'producer': 'Acrobat Distiller 8.1.0 (Windows)', 'creationDate': \"D:20221210111351+05'30'\", 'modDate': \"D:20221210111432+05'30'\", 'trapped': '', 'modal': 'text'}), Document(page_content='induction of remission than prior estimates, and the\\nsigniﬁcantly superior efﬁcacy of ustekinumab and tofa-\\ncitinib over vedolizumab as second-line agents in pa-\\ntients with prior exposure to TNFa antagonists. With\\nlimited head-to-head trials, this information can inform\\nclinical practice and guidelines directly and facilitate\\nshared decision making for management of patients with\\nmoderate–severe ulcerative colitis.\\nOur\\nresults\\nconﬁrm\\nseveral\\nprior\\nobservational\\ncomparative effectiveness studies, individual patient-\\nlevel analyses of clinical trials, and indirect treatment\\ncomparison network meta-analyses suggesting higher\\nefﬁcacy and effectiveness of inﬂiximab over adalimumab\\nand golimumab.4,5,29,30 This may be related to differ-\\nences\\nin\\npharmacokinetics\\nand\\nbioavailability\\nwith\\ndifferent dosing schema (weight-based vs ﬁxed dose)\\nand route of administration. The recent Study to Evaluate\\nthe Safety and Efﬁcacy of Two Drug Regimens in Subjects\\nWith Moderate to Severe Ulcerative Colitis-UC trial\\ncomparing standard- vs high-dose adalimumab in pa-\\ntients with moderate–severe ulcerative colitis failed to\\nshow the superiority of higher-dose adalimumab, sug-\\ngesting that currently approved dosing of adalimumab is\\nunlikely to change, and, hence, the comparative efﬁcacy\\nresults will remain similar.31 Our ﬁndings also support\\nthe observation in the recent head-to-head VARSITY trial\\nas well as propensity score-matched analyses from the\\nVICTORY consortium that vedolizumab is more effective\\nthan adalimumab for long-term maintenance of clinical\\nremission; over 8 to 12 weeks of induction therapy,\\nhowever, no differences were observed between the 2\\nagents.6,32 Moreover, we did not observe any differences\\nin the efﬁcacy of vedolizumab and inﬂiximab in the\\nmaintenance\\nof\\nclinical\\nremission\\nor\\nendoscopic\\n2188 Singh et al\\nClinical Gastroenterology and Hepatology Vol. 18, No. 10', metadata={'source': 'data/document_store/uc/PIIS1542356520300446.pdf', 'file_path': 'data/document_store/uc/PIIS1542356520300446.pdf', 'page': 9, 'total_pages': 19, 'format': 'PDF 1.7', 'title': 'First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis', 'author': 'Siddharth Singh', 'subject': 'Clinical Gastroenterology and Hepatology, 18 (2020) 2179-2197. doi:10.1016/j.cgh.2020.01.008', 'keywords': '', 'creator': 'Elsevier', 'producer': 'Acrobat Distiller 8.1.0 (Windows)', 'creationDate': \"D:20200816062640+05'30'\", 'modDate': \"D:20200816062734+05'30'\", 'trapped': '', 'modal': 'text'}), Document(page_content='What You Need to Know\\nBackground\\nA systematic review and network meta-analysis is\\nneeded to compare efﬁcacy and safety of ﬁrst-line\\n(biologic-naïve) and second-line (prior exposure to\\ntumor necrosis factor [TNF] antagonists) agents for\\ntreatment of moderate to severely active ulcerative\\ncolitis.\\nFindings\\nInﬂiximab was ranked highest in biologic-naïve pa-\\ntients, and ustekinumab and tofacitinib were ranked\\nhighest in patients with prior exposure to TNF an-\\ntagonists, for induction of remission and endoscopic\\nimprovement. More trials of direct comparisons are\\nneeded to inform clinical decision-making with\\ngreater conﬁdence.\\nImplications for patient care\\nPatients with moderate to severely active ulcerative\\ncolitis should receive inﬂiximab or vedolizumab as\\nﬁrst-line therapy, or ustekinumab or tofacitinib if\\nthey have prior exposure to TNF antagonists.\\n2180 Singh et al\\nClinical Gastroenterology and Hepatology Vol. 18, No. 10', metadata={'source': 'data/document_store/uc/PIIS1542356520300446.pdf', 'file_path': 'data/document_store/uc/PIIS1542356520300446.pdf', 'page': 1, 'total_pages': 19, 'format': 'PDF 1.7', 'title': 'First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis', 'author': 'Siddharth Singh', 'subject': 'Clinical Gastroenterology and Hepatology, 18 (2020) 2179-2197. doi:10.1016/j.cgh.2020.01.008', 'keywords': '', 'creator': 'Elsevier', 'producer': 'Acrobat Distiller 8.1.0 (Windows)', 'creationDate': \"D:20200816062640+05'30'\", 'modDate': \"D:20200816062734+05'30'\", 'trapped': '', 'modal': 'text'}), Document(page_content='Burr et al. \\n \\n29 of 45 \\npreferential janus kinase-1 inhibitor, although given filgotinib also has increased selectivity \\nfor janus kinase-1 this cannot be the sole reason for upadacitinib’s higher ranking. Despite \\nthese limitations, the results of our study are still useful for informing treatment decisions for \\npatients with moderate to severely active UC and can be used in future updates of evidence-\\nbased management guidelines.  \\nAn initial network meta-analyses by Singh et al. demonstrated infliximab to be the \\nmost efficacious drug for patients naïve to biological therapies in terms of induction of \\nclinical remission and endoscopic improvement, with vedolizumab ranked second.[22] In \\npatients exposed to biological therapies tofacitinib ranked first for both clinical remission and \\nendoscopic improvement. An update to this work from 2020, including data from head-to-\\nhead trials of vedolizumab and adalimumab, as well as phase III placebo-controlled trials of \\nustekinumab, demonstrated again that infliximab was ranked first for induction of clinical \\nremission and endoscopic improvement in biologic-naïve patients, with ustekinumab and \\ntofacitinib ranked highest in patients previously exposed to biologics.[23] This later network \\nmeta-analysis included 14 induction of remission trials, recruiting almost 5500 patients, \\nalthough the Japanese trial of infliximab versus placebo in 208 patients reported by \\nKobayashi et al. was not included.[42] In contrast to these previous network meta-analyses, \\nour results provide hope that some novel drugs, which are likely to come to market soon, are \\npotentially more efficacious for moderate to severely active UC than existing licensed \\ntherapies. \\nOur results confirm that all available drugs, other than adalimumab 160/160mg, \\nadalimumab 80/40mg, and filgotinib 100mg o.d. were more efficacious than placebo for the \\ntreatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs \\nwere safe and well-tolerated, with no significant increase in serious adverse events or adverse \\nevents leading to withdrawal over the rates seen in the placebo arms, although the RR of', metadata={'source': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'file_path': 'data/document_store/uc/gutjnl-2021-326390R2 CLEAN.pdf', 'page': 29, 'total_pages': 46, 'format': 'PDF 1.7', 'title': 'Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis', 'author': 'Burr, NE, Gracie, DJ, Black, CJ and Ford, AC', 'subject': '', 'keywords': 'meta-analysis; ulcerative colitis', 'creator': 'Microsoft® Word for Microsoft 365', 'producer': 'GPL Ghostscript 9.25', 'creationDate': \"D:20230106151148Z00'00'\", 'modDate': \"D:20230106151148Z00'00'\", 'trapped': '', 'modal': 'text'}), Document(page_content='inﬂux of these cells to distant sites, as suggested by Diaz et al., who\\nobserved de novo extraintestinal manifestations in vedolizumab-treated\\nIBD patients (Diaz et al., 2020). An increased incidence of extra-\\nintestinal manifestation in vedolizumab treated IBD patients have also\\nbeen observed, compared to anti-TNF agents in a large American claims\\ndatabase (Dubinsky et al., 2018). However, by improving disease activity\\nthese drugs could still have an indirect impact on associated EIM, mostly\\nperipheral arthritis, as suggested by the recent EMOTIVE retrospective\\nanalysis (Kopylov et al., 2021). Ustekinumab, however, has also limited\\nrole in this indication, as this drug is also indicated in rheumatoid\\narthritis (Kerschbaumer et al., 2020). Dermatological extraintestinal\\nmanifestations occur in up to 15% of IBD patients (Vavricka et al., 2011).\\nThe most common, erythema nodosum, depends on the underlying dis-\\nease activity, whereas pyoderma gangrenosum may be associated with\\nactive or inactive intestinal disease and requires rapid management, most\\ncommonly with systemic medication. Treatment includes oral cortico-\\nsteroids, cyclosporine, tacrolimus and anti-TNF therapy (inﬂiximab or\\nadalimumab), drugs that have good efﬁcacy in several cases reports and\\nsmall case series (Juillerat et al., 2007). Cases reports and a recent\\nsemi-systematic review suggest that IBD cutaneous lesions may respond\\nto the newer IBD drugs. This is the case for ustekinumab and less\\nfrequently for vedolizumab (Phillips et al., 2020; Ben Abdallah et al.,\\n2021). Uveitis also appears to respond to anti-TNF agents (Leal et al.,\\n2019), whereas no biological agents, despite high expectations for\\nvedolizumab, has shown efﬁcacy in primary sclerosing cholangitis\\n(Christensen et al., 2018; Lynch et al., 2020).\\nFistula development affects up to 50% of CD patients over 20 years of\\ndisease course. Half of these patients experience perianal ﬁstula (Rub-\\nbino et al., 2021). After surgical drainage of pelvic sepsis, medical ther-\\napy may be undertaken. Best results so far are obtained with anti-TNF\\nagents. Among them, only inﬂiximab has been evaluated in a large,\\ndedicated placebo-randomized trial. Out of 366 patients who received\\ninduction with 5 mg/kg inﬂiximab at Week 0, 2 and 6, 195 responders\\nwere randomized to maintenance therapy or placebo. At Week 54, 36%\\nof inﬂiximab treated patients had a complete absence of ﬁstula against', metadata={'source': 'data/document_store/uc/juillerat 2022.pdf', 'file_path': 'data/document_store/uc/juillerat 2022.pdf', 'page': 4, 'total_pages': 9, 'format': 'PDF 1.7', 'title': 'Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?', 'author': 'Pascal Juillerat', 'subject': 'Current Research in Pharmacology and Drug Discovery, 3 (2022) 100104. doi:10.1016/j.crphar.2022.100104', 'keywords': '', 'creator': 'Elsevier', 'producer': 'Acrobat Distiller 8.1.0 (Windows)', 'creationDate': \"D:20221210111351+05'30'\", 'modDate': \"D:20221210111432+05'30'\", 'trapped': '', 'modal': 'text'}), Document(page_content=\"disease); ozanimod as an oral alternative\\n• Infliximab, preferably in combination with  \\n immunomodulators (severe disease,  \\n \\n extraintestinal manifestations)\\n• Ustekinumab (for patients with substantial \\n comorbidities or  contraindications to TNF  \\n antagonists)\\nFirst-line therapy\\n• TNF antagonists: infliximab or adalimumab,  \\n preferably in combination with   \\n \\n \\n immunomodulators\\n• Risankizumab or ustekinumab (for patients  \\n with substantial comorbidities or  \\n \\n \\n contraindications to TNF antagonists)\\nFirst-line therapy\\n• Vedolizumab\\n• Ustekinumab\\nFirst-line therapy\\n• Risankizumab or ustekinumab\\n• Vedolizumab\\nModerate-to-severely active\\nulcerative colitis\\nModerate-to-severely active\\nulcerative colitis\\nModerate-to-severely active\\nCrohn's disease\\nModerate-to-severely active\\nCrohn's disease\\nSecond-line therapy\\n• Upadacitinib (or tofacitinib) (for patients with  \\n prior failure of infliximab)\\n• Infliximab or ustekinumab (for patients with  \\n prior exposure to vedolizumab)\\n• Vedolizumab (moderate disease, for patients  \\n who discontinued first-line biologic agent \\n for intolerance)\\nSecond-line therapy (in patients with prior \\nexposure to infliximab or adalimumab)\\n• Risankizumab or ustekinumab\\n• Second TNF antagonist (for patients with  \\n loss of response owing to immunogenicity,  \\n or  intolerance, to first TNF antagonist)\\nSecond-line therapy\\n• Ozanimod\\n• Infliximab monotherapy\\n• Upadacitinib (or tofacitinib)\\nSecond-line therapy\\n• Infliximab or adalimumab   \\n monotherapy\\nRisk averse\\n• Prior serious infections\\n• Prior malignancy\\n• Older age, multiple comorbidities\\nSevere disease\\n• High structural damage\\n• High inflammatory burden\\n• Significant efect on quality of life\\nPatients’ values and preferences\\n(lifestyle and logistics, speed of onset, costs)\\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \\nCrohn’s disease and moderate-to-severe ulcerative colitis. The algorithm \\nintegrates data on comparative effectiveness and safety of therapies in the \\ncontext of an individual patient’s risk of disease-related and treatment-related \\ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \\nref. 10, Elsevier.\", metadata={'source': 'data/document_store/uc/positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf', 'file_path': 'data/document_store/uc/positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf', 'page': 1, 'total_pages': 2, 'format': 'PDF 1.6', 'title': 'Positioning therapies for the management of inflammatory bowel disease', 'author': 'Siddharth Singh', 'subject': 'Nature Reviews Gastroenterology & Hepatology, doi:10.1038/s41575-023-00744-9', 'keywords': '', 'creator': 'Springer', 'producer': '', 'creationDate': \"D:20230621105639+05'30'\", 'modDate': \"D:20230627215608+08'00'\", 'trapped': '', 'modal': 'text'}), Document(page_content='Volume 20 | July 2023 | 411–412 | 411\\nnature reviews gastroenterology & hepatology\\nhttps://doi.org/10.1038/s41575-023-00744-9\\nClinical outlook\\nPositioning therapies for the management \\nof inflammatory bowel disease\\nSiddharth Singh\\nA careful integration of the effectiveness and \\nsafety of the therapies for inflammatory bowel \\ndisease, considering patients’ disease risks, \\ntreatment complications and preferences, \\nis warranted to inform the positioning of \\ntherapies in clinical practice. Precision \\nmedicine might help choose the best option  \\nfor an individual patient.\\nOver the past decade, treatment options for the management of inflam-\\nmatory bowel disease (IBD) have expanded remarkably. After the regu-\\nlatory approval of infliximab targeting tumour necrosis factor (TNF) in \\n1998, the regulatory approval of vedolizumab, an anti-α4β7 integrin, \\nfollowed in 2014 (barring the approval of natalizumab, an anti-α4 integrin \\nfor Crohn’s disease in 2005, which is used infrequently owing to risk of \\nprogressive multifocal leukoencephalopathy)1. Since 2014, three more \\nclasses of biologic agents and oral small-molecule drugs with unique \\nmechanisms of action with varying efficacy and safety profiles have been \\napproved for the management of IBD: IL-12 and IL-23 antagonists (IL-12p40 \\nand IL-23p40 antagonist, ustekinumab, in 2016; IL-23p19 antagonist, \\nrisankizumab, in 2022 — Crohn’s disease), Janus tyrosine kinase (JAK) \\ninhibitors (a pan-JAK inhibitor, tofacitinib in 2019; selective JAK1 inhib-\\nitors, upadacitinib and filgotinib in 2022 — ulcerative colitis) and a sphin-\\ngosine 1-phosphate receptor modulator (ozanimod, in 2021 — ulcerative \\ncolitis)2. These advances have brought into focus aspects of comparative \\neffectiveness and safety of different therapies and precision medicine to \\nchoose the right drug, for the right patient, at the right time. This Clinical \\nOutlook aims to highlight the current approach to positioning therapies \\nfor the management of moderate-to-severe IBD, relying on careful inte-\\ngration of the medication’s effectiveness and safety in the context of a \\npatient’s risk of disease-related and treatment-related complications and \\npreferences. In addition, it provides a glimpse of how precision medicine \\nmight help choose the best therapy for an individual patient.\\nIn patients with moderate-to-severe Crohn’s disease, the SEAVUE \\ntrial demonstrated that ustekinumab monotherapy is not superior', metadata={'source': 'data/document_store/uc/positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf', 'file_path': 'data/document_store/uc/positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf', 'page': 0, 'total_pages': 2, 'format': 'PDF 1.6', 'title': 'Positioning therapies for the management of inflammatory bowel disease', 'author': 'Siddharth Singh', 'subject': 'Nature Reviews Gastroenterology & Hepatology, doi:10.1038/s41575-023-00744-9', 'keywords': '', 'creator': 'Springer', 'producer': '', 'creationDate': \"D:20230621105639+05'30'\", 'modDate': \"D:20230627215608+08'00'\", 'trapped': '', 'modal': 'text'}), Document(page_content=\"Association: “Technical Review, the Medical Management of Moderate to\\nSevere Luminal and Perianal Fistulizing Crohn's Disease”, the question of\\ncomparing the efﬁcacy between all available biologics is addressed\\n(Singh et al., 2021). The conclusion was that in biologic-naïve patients\\nwith moderate to severely active CD, inﬂiximab, adalimumab, and\\nustekinumab are the most effective compared to vedolizumab and cer-\\ntolizumab pegol. Inﬂiximab was considered the strongest for induction.\\nHowever, in patients exposed to anti-TNF agents (mostly to inﬂiximab),\\nthe beneﬁt of one biological agent over the other remains uncertain. A\\nsummary of the efﬁcacies of the various biological agents, according to\\nthe line of treatment and previous treatment failures and patients'\\nphenotype, is provided in Table 2. The ﬁnal word about the efﬁcacy of\\nbiologics in IBD and the theoretical “therapeutic ceiling” which cannot be\\nbroken (Alsoud et al., 2021) could potentially come from combining\\nthese agents such as demonstrated by the recent VEGA study. This 3-arm\\ntrial presented as one of the highlights of the recent ECCO congress 2022,\\ncompared golimumab (GOL), guselkumab (GUS) and their combined use\\nduring induction period of 12 weeks. This showed a signiﬁcant higher\\nrate of clinical response (83% for combination therapy vs. 75% for GUS\\n(p ¼ 0.215) and 61% for GOL (p ¼ 0.003)) and clinical remission (47%\\nfor combination therapy vs. 24% for GUS (p ¼ 0.005) and 25% for GOL\\n(p ¼ 0.007) based on modiﬁed Mayo score) without added risks for safety\\nin moderate to severely active UC patients naïve to biologics (Sands et al.,\\n2022).\\n3. Personalizing choice of biologic\\n3.1. Prior biologic exposure\\nIn current clinical practice we are confronted with numerous options\\nof treatment sequencing. Personalizing IBD treatment depends on pre-\\nvious drug exposure IBD (1st, 2nd, 3rd line of treatment), prior treatment\\nresponse, comorbidities, safety proﬁle, patient preferences and patient\\nrisk for future IBD complications (disease severity). For example, primary\\nnon response to an anti-TNF was found to be a predictor for diminished\\ntreatment efﬁcacy with an anti-integrin biologic (Singh et al., 2018c).\\nFirst and second line agent treatment sequences and treatment response\\nhave been presented in the previous chapter. However, data are even\\nscarcer concerning third line of treatment after two anti-TNFs exposure.\\nA retrospective small series of 67 patients with Crohn's disease treated\", metadata={'source': 'data/document_store/uc/juillerat 2022.pdf', 'file_path': 'data/document_store/uc/juillerat 2022.pdf', 'page': 2, 'total_pages': 9, 'format': 'PDF 1.7', 'title': 'Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?', 'author': 'Pascal Juillerat', 'subject': 'Current Research in Pharmacology and Drug Discovery, 3 (2022) 100104. doi:10.1016/j.crphar.2022.100104', 'keywords': '', 'creator': 'Elsevier', 'producer': 'Acrobat Distiller 8.1.0 (Windows)', 'creationDate': \"D:20221210111351+05'30'\", 'modDate': \"D:20221210111432+05'30'\", 'trapped': '', 'modal': 'text'})]}\u001b[0m\n",
      "Thought:"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 4.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 8.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n",
      "Retrying langchain.chat_models.openai.ChatOpenAI.completion_with_retry.<locals>._completion_with_retry in 10.0 seconds as it raised RateLimitError: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues..\n"
     ]
    },
    {
     "ename": "RateLimitError",
     "evalue": "Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues.",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mRateLimitError\u001b[0m                            Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[8], line 2\u001b[0m\n\u001b[1;32m      1\u001b[0m sample_case \u001b[39m=\u001b[39m test_cases[\u001b[39m0\u001b[39m]\n\u001b[0;32m----> 2\u001b[0m agent_executor(sample_case)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chains/base.py:258\u001b[0m, in \u001b[0;36mChain.__call__\u001b[0;34m(self, inputs, return_only_outputs, callbacks, tags, metadata, include_run_info)\u001b[0m\n\u001b[1;32m    256\u001b[0m \u001b[39mexcept\u001b[39;00m (\u001b[39mKeyboardInterrupt\u001b[39;00m, \u001b[39mException\u001b[39;00m) \u001b[39mas\u001b[39;00m e:\n\u001b[1;32m    257\u001b[0m     run_manager\u001b[39m.\u001b[39mon_chain_error(e)\n\u001b[0;32m--> 258\u001b[0m     \u001b[39mraise\u001b[39;00m e\n\u001b[1;32m    259\u001b[0m run_manager\u001b[39m.\u001b[39mon_chain_end(outputs)\n\u001b[1;32m    260\u001b[0m final_outputs: Dict[\u001b[39mstr\u001b[39m, Any] \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mprep_outputs(\n\u001b[1;32m    261\u001b[0m     inputs, outputs, return_only_outputs\n\u001b[1;32m    262\u001b[0m )\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chains/base.py:252\u001b[0m, in \u001b[0;36mChain.__call__\u001b[0;34m(self, inputs, return_only_outputs, callbacks, tags, metadata, include_run_info)\u001b[0m\n\u001b[1;32m    246\u001b[0m run_manager \u001b[39m=\u001b[39m callback_manager\u001b[39m.\u001b[39mon_chain_start(\n\u001b[1;32m    247\u001b[0m     dumpd(\u001b[39mself\u001b[39m),\n\u001b[1;32m    248\u001b[0m     inputs,\n\u001b[1;32m    249\u001b[0m )\n\u001b[1;32m    250\u001b[0m \u001b[39mtry\u001b[39;00m:\n\u001b[1;32m    251\u001b[0m     outputs \u001b[39m=\u001b[39m (\n\u001b[0;32m--> 252\u001b[0m         \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_call(inputs, run_manager\u001b[39m=\u001b[39;49mrun_manager)\n\u001b[1;32m    253\u001b[0m         \u001b[39mif\u001b[39;00m new_arg_supported\n\u001b[1;32m    254\u001b[0m         \u001b[39melse\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_call(inputs)\n\u001b[1;32m    255\u001b[0m     )\n\u001b[1;32m    256\u001b[0m \u001b[39mexcept\u001b[39;00m (\u001b[39mKeyboardInterrupt\u001b[39;00m, \u001b[39mException\u001b[39;00m) \u001b[39mas\u001b[39;00m e:\n\u001b[1;32m    257\u001b[0m     run_manager\u001b[39m.\u001b[39mon_chain_error(e)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/agents/agent.py:1029\u001b[0m, in \u001b[0;36mAgentExecutor._call\u001b[0;34m(self, inputs, run_manager)\u001b[0m\n\u001b[1;32m   1027\u001b[0m \u001b[39m# We now enter the agent loop (until it returns something).\u001b[39;00m\n\u001b[1;32m   1028\u001b[0m \u001b[39mwhile\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_should_continue(iterations, time_elapsed):\n\u001b[0;32m-> 1029\u001b[0m     next_step_output \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_take_next_step(\n\u001b[1;32m   1030\u001b[0m         name_to_tool_map,\n\u001b[1;32m   1031\u001b[0m         color_mapping,\n\u001b[1;32m   1032\u001b[0m         inputs,\n\u001b[1;32m   1033\u001b[0m         intermediate_steps,\n\u001b[1;32m   1034\u001b[0m         run_manager\u001b[39m=\u001b[39;49mrun_manager,\n\u001b[1;32m   1035\u001b[0m     )\n\u001b[1;32m   1036\u001b[0m     \u001b[39mif\u001b[39;00m \u001b[39misinstance\u001b[39m(next_step_output, AgentFinish):\n\u001b[1;32m   1037\u001b[0m         \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_return(\n\u001b[1;32m   1038\u001b[0m             next_step_output, intermediate_steps, run_manager\u001b[39m=\u001b[39mrun_manager\n\u001b[1;32m   1039\u001b[0m         )\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/agents/agent.py:832\u001b[0m, in \u001b[0;36mAgentExecutor._take_next_step\u001b[0;34m(self, name_to_tool_map, color_mapping, inputs, intermediate_steps, run_manager)\u001b[0m\n\u001b[1;32m    829\u001b[0m     intermediate_steps \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_prepare_intermediate_steps(intermediate_steps)\n\u001b[1;32m    831\u001b[0m     \u001b[39m# Call the LLM to see what to do.\u001b[39;00m\n\u001b[0;32m--> 832\u001b[0m     output \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49magent\u001b[39m.\u001b[39;49mplan(\n\u001b[1;32m    833\u001b[0m         intermediate_steps,\n\u001b[1;32m    834\u001b[0m         callbacks\u001b[39m=\u001b[39;49mrun_manager\u001b[39m.\u001b[39;49mget_child() \u001b[39mif\u001b[39;49;00m run_manager \u001b[39melse\u001b[39;49;00m \u001b[39mNone\u001b[39;49;00m,\n\u001b[1;32m    835\u001b[0m         \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49minputs,\n\u001b[1;32m    836\u001b[0m     )\n\u001b[1;32m    837\u001b[0m \u001b[39mexcept\u001b[39;00m OutputParserException \u001b[39mas\u001b[39;00m e:\n\u001b[1;32m    838\u001b[0m     \u001b[39mif\u001b[39;00m \u001b[39misinstance\u001b[39m(\u001b[39mself\u001b[39m\u001b[39m.\u001b[39mhandle_parsing_errors, \u001b[39mbool\u001b[39m):\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/agents/agent.py:456\u001b[0m, in \u001b[0;36mAgent.plan\u001b[0;34m(self, intermediate_steps, callbacks, **kwargs)\u001b[0m\n\u001b[1;32m    444\u001b[0m \u001b[39m\u001b[39m\u001b[39m\"\"\"Given input, decided what to do.\u001b[39;00m\n\u001b[1;32m    445\u001b[0m \n\u001b[1;32m    446\u001b[0m \u001b[39mArgs:\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    453\u001b[0m \u001b[39m    Action specifying what tool to use.\u001b[39;00m\n\u001b[1;32m    454\u001b[0m \u001b[39m\"\"\"\u001b[39;00m\n\u001b[1;32m    455\u001b[0m full_inputs \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mget_full_inputs(intermediate_steps, \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs)\n\u001b[0;32m--> 456\u001b[0m full_output \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mllm_chain\u001b[39m.\u001b[39;49mpredict(callbacks\u001b[39m=\u001b[39;49mcallbacks, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mfull_inputs)\n\u001b[1;32m    457\u001b[0m \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39moutput_parser\u001b[39m.\u001b[39mparse(full_output)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chains/llm.py:252\u001b[0m, in \u001b[0;36mLLMChain.predict\u001b[0;34m(self, callbacks, **kwargs)\u001b[0m\n\u001b[1;32m    237\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mpredict\u001b[39m(\u001b[39mself\u001b[39m, callbacks: Callbacks \u001b[39m=\u001b[39m \u001b[39mNone\u001b[39;00m, \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs: Any) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m \u001b[39mstr\u001b[39m:\n\u001b[1;32m    238\u001b[0m \u001b[39m    \u001b[39m\u001b[39m\"\"\"Format prompt with kwargs and pass to LLM.\u001b[39;00m\n\u001b[1;32m    239\u001b[0m \n\u001b[1;32m    240\u001b[0m \u001b[39m    Args:\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    250\u001b[0m \u001b[39m            completion = llm.predict(adjective=\"funny\")\u001b[39;00m\n\u001b[1;32m    251\u001b[0m \u001b[39m    \"\"\"\u001b[39;00m\n\u001b[0;32m--> 252\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39;49m(kwargs, callbacks\u001b[39m=\u001b[39;49mcallbacks)[\u001b[39mself\u001b[39m\u001b[39m.\u001b[39moutput_key]\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chains/base.py:258\u001b[0m, in \u001b[0;36mChain.__call__\u001b[0;34m(self, inputs, return_only_outputs, callbacks, tags, metadata, include_run_info)\u001b[0m\n\u001b[1;32m    256\u001b[0m \u001b[39mexcept\u001b[39;00m (\u001b[39mKeyboardInterrupt\u001b[39;00m, \u001b[39mException\u001b[39;00m) \u001b[39mas\u001b[39;00m e:\n\u001b[1;32m    257\u001b[0m     run_manager\u001b[39m.\u001b[39mon_chain_error(e)\n\u001b[0;32m--> 258\u001b[0m     \u001b[39mraise\u001b[39;00m e\n\u001b[1;32m    259\u001b[0m run_manager\u001b[39m.\u001b[39mon_chain_end(outputs)\n\u001b[1;32m    260\u001b[0m final_outputs: Dict[\u001b[39mstr\u001b[39m, Any] \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mprep_outputs(\n\u001b[1;32m    261\u001b[0m     inputs, outputs, return_only_outputs\n\u001b[1;32m    262\u001b[0m )\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chains/base.py:252\u001b[0m, in \u001b[0;36mChain.__call__\u001b[0;34m(self, inputs, return_only_outputs, callbacks, tags, metadata, include_run_info)\u001b[0m\n\u001b[1;32m    246\u001b[0m run_manager \u001b[39m=\u001b[39m callback_manager\u001b[39m.\u001b[39mon_chain_start(\n\u001b[1;32m    247\u001b[0m     dumpd(\u001b[39mself\u001b[39m),\n\u001b[1;32m    248\u001b[0m     inputs,\n\u001b[1;32m    249\u001b[0m )\n\u001b[1;32m    250\u001b[0m \u001b[39mtry\u001b[39;00m:\n\u001b[1;32m    251\u001b[0m     outputs \u001b[39m=\u001b[39m (\n\u001b[0;32m--> 252\u001b[0m         \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_call(inputs, run_manager\u001b[39m=\u001b[39;49mrun_manager)\n\u001b[1;32m    253\u001b[0m         \u001b[39mif\u001b[39;00m new_arg_supported\n\u001b[1;32m    254\u001b[0m         \u001b[39melse\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_call(inputs)\n\u001b[1;32m    255\u001b[0m     )\n\u001b[1;32m    256\u001b[0m \u001b[39mexcept\u001b[39;00m (\u001b[39mKeyboardInterrupt\u001b[39;00m, \u001b[39mException\u001b[39;00m) \u001b[39mas\u001b[39;00m e:\n\u001b[1;32m    257\u001b[0m     run_manager\u001b[39m.\u001b[39mon_chain_error(e)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chains/llm.py:92\u001b[0m, in \u001b[0;36mLLMChain._call\u001b[0;34m(self, inputs, run_manager)\u001b[0m\n\u001b[1;32m     87\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39m_call\u001b[39m(\n\u001b[1;32m     88\u001b[0m     \u001b[39mself\u001b[39m,\n\u001b[1;32m     89\u001b[0m     inputs: Dict[\u001b[39mstr\u001b[39m, Any],\n\u001b[1;32m     90\u001b[0m     run_manager: Optional[CallbackManagerForChainRun] \u001b[39m=\u001b[39m \u001b[39mNone\u001b[39;00m,\n\u001b[1;32m     91\u001b[0m ) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m Dict[\u001b[39mstr\u001b[39m, \u001b[39mstr\u001b[39m]:\n\u001b[0;32m---> 92\u001b[0m     response \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mgenerate([inputs], run_manager\u001b[39m=\u001b[39;49mrun_manager)\n\u001b[1;32m     93\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mcreate_outputs(response)[\u001b[39m0\u001b[39m]\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chains/llm.py:102\u001b[0m, in \u001b[0;36mLLMChain.generate\u001b[0;34m(self, input_list, run_manager)\u001b[0m\n\u001b[1;32m    100\u001b[0m \u001b[39m\u001b[39m\u001b[39m\"\"\"Generate LLM result from inputs.\"\"\"\u001b[39;00m\n\u001b[1;32m    101\u001b[0m prompts, stop \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mprep_prompts(input_list, run_manager\u001b[39m=\u001b[39mrun_manager)\n\u001b[0;32m--> 102\u001b[0m \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mllm\u001b[39m.\u001b[39;49mgenerate_prompt(\n\u001b[1;32m    103\u001b[0m     prompts,\n\u001b[1;32m    104\u001b[0m     stop,\n\u001b[1;32m    105\u001b[0m     callbacks\u001b[39m=\u001b[39;49mrun_manager\u001b[39m.\u001b[39;49mget_child() \u001b[39mif\u001b[39;49;00m run_manager \u001b[39melse\u001b[39;49;00m \u001b[39mNone\u001b[39;49;00m,\n\u001b[1;32m    106\u001b[0m     \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49m\u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mllm_kwargs,\n\u001b[1;32m    107\u001b[0m )\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chat_models/base.py:401\u001b[0m, in \u001b[0;36mBaseChatModel.generate_prompt\u001b[0;34m(self, prompts, stop, callbacks, **kwargs)\u001b[0m\n\u001b[1;32m    393\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mgenerate_prompt\u001b[39m(\n\u001b[1;32m    394\u001b[0m     \u001b[39mself\u001b[39m,\n\u001b[1;32m    395\u001b[0m     prompts: List[PromptValue],\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    398\u001b[0m     \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs: Any,\n\u001b[1;32m    399\u001b[0m ) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m LLMResult:\n\u001b[1;32m    400\u001b[0m     prompt_messages \u001b[39m=\u001b[39m [p\u001b[39m.\u001b[39mto_messages() \u001b[39mfor\u001b[39;00m p \u001b[39min\u001b[39;00m prompts]\n\u001b[0;32m--> 401\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mgenerate(prompt_messages, stop\u001b[39m=\u001b[39;49mstop, callbacks\u001b[39m=\u001b[39;49mcallbacks, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chat_models/base.py:296\u001b[0m, in \u001b[0;36mBaseChatModel.generate\u001b[0;34m(self, messages, stop, callbacks, tags, metadata, **kwargs)\u001b[0m\n\u001b[1;32m    294\u001b[0m         \u001b[39mif\u001b[39;00m run_managers:\n\u001b[1;32m    295\u001b[0m             run_managers[i]\u001b[39m.\u001b[39mon_llm_error(e)\n\u001b[0;32m--> 296\u001b[0m         \u001b[39mraise\u001b[39;00m e\n\u001b[1;32m    297\u001b[0m flattened_outputs \u001b[39m=\u001b[39m [\n\u001b[1;32m    298\u001b[0m     LLMResult(generations\u001b[39m=\u001b[39m[res\u001b[39m.\u001b[39mgenerations], llm_output\u001b[39m=\u001b[39mres\u001b[39m.\u001b[39mllm_output)\n\u001b[1;32m    299\u001b[0m     \u001b[39mfor\u001b[39;00m res \u001b[39min\u001b[39;00m results\n\u001b[1;32m    300\u001b[0m ]\n\u001b[1;32m    301\u001b[0m llm_output \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_combine_llm_outputs([res\u001b[39m.\u001b[39mllm_output \u001b[39mfor\u001b[39;00m res \u001b[39min\u001b[39;00m results])\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chat_models/base.py:286\u001b[0m, in \u001b[0;36mBaseChatModel.generate\u001b[0;34m(self, messages, stop, callbacks, tags, metadata, **kwargs)\u001b[0m\n\u001b[1;32m    283\u001b[0m \u001b[39mfor\u001b[39;00m i, m \u001b[39min\u001b[39;00m \u001b[39menumerate\u001b[39m(messages):\n\u001b[1;32m    284\u001b[0m     \u001b[39mtry\u001b[39;00m:\n\u001b[1;32m    285\u001b[0m         results\u001b[39m.\u001b[39mappend(\n\u001b[0;32m--> 286\u001b[0m             \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_generate_with_cache(\n\u001b[1;32m    287\u001b[0m                 m,\n\u001b[1;32m    288\u001b[0m                 stop\u001b[39m=\u001b[39;49mstop,\n\u001b[1;32m    289\u001b[0m                 run_manager\u001b[39m=\u001b[39;49mrun_managers[i] \u001b[39mif\u001b[39;49;00m run_managers \u001b[39melse\u001b[39;49;00m \u001b[39mNone\u001b[39;49;00m,\n\u001b[1;32m    290\u001b[0m                 \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs,\n\u001b[1;32m    291\u001b[0m             )\n\u001b[1;32m    292\u001b[0m         )\n\u001b[1;32m    293\u001b[0m     \u001b[39mexcept\u001b[39;00m (\u001b[39mKeyboardInterrupt\u001b[39;00m, \u001b[39mException\u001b[39;00m) \u001b[39mas\u001b[39;00m e:\n\u001b[1;32m    294\u001b[0m         \u001b[39mif\u001b[39;00m run_managers:\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chat_models/base.py:433\u001b[0m, in \u001b[0;36mBaseChatModel._generate_with_cache\u001b[0;34m(self, messages, stop, run_manager, **kwargs)\u001b[0m\n\u001b[1;32m    429\u001b[0m     \u001b[39mraise\u001b[39;00m \u001b[39mValueError\u001b[39;00m(\n\u001b[1;32m    430\u001b[0m         \u001b[39m\"\u001b[39m\u001b[39mAsked to cache, but no cache found at `langchain.cache`.\u001b[39m\u001b[39m\"\u001b[39m\n\u001b[1;32m    431\u001b[0m     )\n\u001b[1;32m    432\u001b[0m \u001b[39mif\u001b[39;00m new_arg_supported:\n\u001b[0;32m--> 433\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_generate(\n\u001b[1;32m    434\u001b[0m         messages, stop\u001b[39m=\u001b[39;49mstop, run_manager\u001b[39m=\u001b[39;49mrun_manager, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs\n\u001b[1;32m    435\u001b[0m     )\n\u001b[1;32m    436\u001b[0m \u001b[39melse\u001b[39;00m:\n\u001b[1;32m    437\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_generate(messages, stop\u001b[39m=\u001b[39mstop, \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chat_models/openai.py:400\u001b[0m, in \u001b[0;36mChatOpenAI._generate\u001b[0;34m(self, messages, stop, run_manager, **kwargs)\u001b[0m\n\u001b[1;32m    398\u001b[0m message_dicts, params \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_create_message_dicts(messages, stop)\n\u001b[1;32m    399\u001b[0m params \u001b[39m=\u001b[39m {\u001b[39m*\u001b[39m\u001b[39m*\u001b[39mparams, \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs}\n\u001b[0;32m--> 400\u001b[0m response \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mcompletion_with_retry(\n\u001b[1;32m    401\u001b[0m     messages\u001b[39m=\u001b[39;49mmessage_dicts, run_manager\u001b[39m=\u001b[39;49mrun_manager, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mparams\n\u001b[1;32m    402\u001b[0m )\n\u001b[1;32m    403\u001b[0m \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_create_chat_result(response)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chat_models/openai.py:340\u001b[0m, in \u001b[0;36mChatOpenAI.completion_with_retry\u001b[0;34m(self, run_manager, **kwargs)\u001b[0m\n\u001b[1;32m    336\u001b[0m \u001b[39m@retry_decorator\u001b[39m\n\u001b[1;32m    337\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39m_completion_with_retry\u001b[39m(\u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs: Any) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m Any:\n\u001b[1;32m    338\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mclient\u001b[39m.\u001b[39mcreate(\u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs)\n\u001b[0;32m--> 340\u001b[0m \u001b[39mreturn\u001b[39;00m _completion_with_retry(\u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/tenacity/__init__.py:289\u001b[0m, in \u001b[0;36mBaseRetrying.wraps.<locals>.wrapped_f\u001b[0;34m(*args, **kw)\u001b[0m\n\u001b[1;32m    287\u001b[0m \u001b[39m@functools\u001b[39m\u001b[39m.\u001b[39mwraps(f)\n\u001b[1;32m    288\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mwrapped_f\u001b[39m(\u001b[39m*\u001b[39margs: t\u001b[39m.\u001b[39mAny, \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkw: t\u001b[39m.\u001b[39mAny) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m t\u001b[39m.\u001b[39mAny:\n\u001b[0;32m--> 289\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39;49m(f, \u001b[39m*\u001b[39;49margs, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkw)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/tenacity/__init__.py:379\u001b[0m, in \u001b[0;36mRetrying.__call__\u001b[0;34m(self, fn, *args, **kwargs)\u001b[0m\n\u001b[1;32m    377\u001b[0m retry_state \u001b[39m=\u001b[39m RetryCallState(retry_object\u001b[39m=\u001b[39m\u001b[39mself\u001b[39m, fn\u001b[39m=\u001b[39mfn, args\u001b[39m=\u001b[39margs, kwargs\u001b[39m=\u001b[39mkwargs)\n\u001b[1;32m    378\u001b[0m \u001b[39mwhile\u001b[39;00m \u001b[39mTrue\u001b[39;00m:\n\u001b[0;32m--> 379\u001b[0m     do \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49miter(retry_state\u001b[39m=\u001b[39;49mretry_state)\n\u001b[1;32m    380\u001b[0m     \u001b[39mif\u001b[39;00m \u001b[39misinstance\u001b[39m(do, DoAttempt):\n\u001b[1;32m    381\u001b[0m         \u001b[39mtry\u001b[39;00m:\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/tenacity/__init__.py:325\u001b[0m, in \u001b[0;36mBaseRetrying.iter\u001b[0;34m(self, retry_state)\u001b[0m\n\u001b[1;32m    323\u001b[0m     retry_exc \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mretry_error_cls(fut)\n\u001b[1;32m    324\u001b[0m     \u001b[39mif\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mreraise:\n\u001b[0;32m--> 325\u001b[0m         \u001b[39mraise\u001b[39;00m retry_exc\u001b[39m.\u001b[39;49mreraise()\n\u001b[1;32m    326\u001b[0m     \u001b[39mraise\u001b[39;00m retry_exc \u001b[39mfrom\u001b[39;00m \u001b[39mfut\u001b[39;00m\u001b[39m.\u001b[39;00m\u001b[39mexception\u001b[39;00m()\n\u001b[1;32m    328\u001b[0m \u001b[39mif\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mwait:\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/tenacity/__init__.py:158\u001b[0m, in \u001b[0;36mRetryError.reraise\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    156\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mreraise\u001b[39m(\u001b[39mself\u001b[39m) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m t\u001b[39m.\u001b[39mNoReturn:\n\u001b[1;32m    157\u001b[0m     \u001b[39mif\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mlast_attempt\u001b[39m.\u001b[39mfailed:\n\u001b[0;32m--> 158\u001b[0m         \u001b[39mraise\u001b[39;00m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mlast_attempt\u001b[39m.\u001b[39;49mresult()\n\u001b[1;32m    159\u001b[0m     \u001b[39mraise\u001b[39;00m \u001b[39mself\u001b[39m\n",
      "File \u001b[0;32m/usr/lib/python3.10/concurrent/futures/_base.py:451\u001b[0m, in \u001b[0;36mFuture.result\u001b[0;34m(self, timeout)\u001b[0m\n\u001b[1;32m    449\u001b[0m     \u001b[39mraise\u001b[39;00m CancelledError()\n\u001b[1;32m    450\u001b[0m \u001b[39melif\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_state \u001b[39m==\u001b[39m FINISHED:\n\u001b[0;32m--> 451\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m__get_result()\n\u001b[1;32m    453\u001b[0m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_condition\u001b[39m.\u001b[39mwait(timeout)\n\u001b[1;32m    455\u001b[0m \u001b[39mif\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_state \u001b[39min\u001b[39;00m [CANCELLED, CANCELLED_AND_NOTIFIED]:\n",
      "File \u001b[0;32m/usr/lib/python3.10/concurrent/futures/_base.py:403\u001b[0m, in \u001b[0;36mFuture.__get_result\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    401\u001b[0m \u001b[39mif\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_exception:\n\u001b[1;32m    402\u001b[0m     \u001b[39mtry\u001b[39;00m:\n\u001b[0;32m--> 403\u001b[0m         \u001b[39mraise\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_exception\n\u001b[1;32m    404\u001b[0m     \u001b[39mfinally\u001b[39;00m:\n\u001b[1;32m    405\u001b[0m         \u001b[39m# Break a reference cycle with the exception in self._exception\u001b[39;00m\n\u001b[1;32m    406\u001b[0m         \u001b[39mself\u001b[39m \u001b[39m=\u001b[39m \u001b[39mNone\u001b[39;00m\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/tenacity/__init__.py:382\u001b[0m, in \u001b[0;36mRetrying.__call__\u001b[0;34m(self, fn, *args, **kwargs)\u001b[0m\n\u001b[1;32m    380\u001b[0m \u001b[39mif\u001b[39;00m \u001b[39misinstance\u001b[39m(do, DoAttempt):\n\u001b[1;32m    381\u001b[0m     \u001b[39mtry\u001b[39;00m:\n\u001b[0;32m--> 382\u001b[0m         result \u001b[39m=\u001b[39m fn(\u001b[39m*\u001b[39;49margs, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n\u001b[1;32m    383\u001b[0m     \u001b[39mexcept\u001b[39;00m \u001b[39mBaseException\u001b[39;00m:  \u001b[39m# noqa: B902\u001b[39;00m\n\u001b[1;32m    384\u001b[0m         retry_state\u001b[39m.\u001b[39mset_exception(sys\u001b[39m.\u001b[39mexc_info())  \u001b[39m# type: ignore[arg-type]\u001b[39;00m\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/langchain/chat_models/openai.py:338\u001b[0m, in \u001b[0;36mChatOpenAI.completion_with_retry.<locals>._completion_with_retry\u001b[0;34m(**kwargs)\u001b[0m\n\u001b[1;32m    336\u001b[0m \u001b[39m@retry_decorator\u001b[39m\n\u001b[1;32m    337\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39m_completion_with_retry\u001b[39m(\u001b[39m*\u001b[39m\u001b[39m*\u001b[39mkwargs: Any) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m Any:\n\u001b[0;32m--> 338\u001b[0m     \u001b[39mreturn\u001b[39;00m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49mclient\u001b[39m.\u001b[39;49mcreate(\u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/openai/api_resources/chat_completion.py:25\u001b[0m, in \u001b[0;36mChatCompletion.create\u001b[0;34m(cls, *args, **kwargs)\u001b[0m\n\u001b[1;32m     23\u001b[0m \u001b[39mwhile\u001b[39;00m \u001b[39mTrue\u001b[39;00m:\n\u001b[1;32m     24\u001b[0m     \u001b[39mtry\u001b[39;00m:\n\u001b[0;32m---> 25\u001b[0m         \u001b[39mreturn\u001b[39;00m \u001b[39msuper\u001b[39;49m()\u001b[39m.\u001b[39;49mcreate(\u001b[39m*\u001b[39;49margs, \u001b[39m*\u001b[39;49m\u001b[39m*\u001b[39;49mkwargs)\n\u001b[1;32m     26\u001b[0m     \u001b[39mexcept\u001b[39;00m TryAgain \u001b[39mas\u001b[39;00m e:\n\u001b[1;32m     27\u001b[0m         \u001b[39mif\u001b[39;00m timeout \u001b[39mis\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39mNone\u001b[39;00m \u001b[39mand\u001b[39;00m time\u001b[39m.\u001b[39mtime() \u001b[39m>\u001b[39m start \u001b[39m+\u001b[39m timeout:\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/openai/api_resources/abstract/engine_api_resource.py:153\u001b[0m, in \u001b[0;36mEngineAPIResource.create\u001b[0;34m(cls, api_key, api_base, api_type, request_id, api_version, organization, **params)\u001b[0m\n\u001b[1;32m    127\u001b[0m \u001b[39m@classmethod\u001b[39m\n\u001b[1;32m    128\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mcreate\u001b[39m(\n\u001b[1;32m    129\u001b[0m     \u001b[39mcls\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    136\u001b[0m     \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mparams,\n\u001b[1;32m    137\u001b[0m ):\n\u001b[1;32m    138\u001b[0m     (\n\u001b[1;32m    139\u001b[0m         deployment_id,\n\u001b[1;32m    140\u001b[0m         engine,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    150\u001b[0m         api_key, api_base, api_type, api_version, organization, \u001b[39m*\u001b[39m\u001b[39m*\u001b[39mparams\n\u001b[1;32m    151\u001b[0m     )\n\u001b[0;32m--> 153\u001b[0m     response, _, api_key \u001b[39m=\u001b[39m requestor\u001b[39m.\u001b[39;49mrequest(\n\u001b[1;32m    154\u001b[0m         \u001b[39m\"\u001b[39;49m\u001b[39mpost\u001b[39;49m\u001b[39m\"\u001b[39;49m,\n\u001b[1;32m    155\u001b[0m         url,\n\u001b[1;32m    156\u001b[0m         params\u001b[39m=\u001b[39;49mparams,\n\u001b[1;32m    157\u001b[0m         headers\u001b[39m=\u001b[39;49mheaders,\n\u001b[1;32m    158\u001b[0m         stream\u001b[39m=\u001b[39;49mstream,\n\u001b[1;32m    159\u001b[0m         request_id\u001b[39m=\u001b[39;49mrequest_id,\n\u001b[1;32m    160\u001b[0m         request_timeout\u001b[39m=\u001b[39;49mrequest_timeout,\n\u001b[1;32m    161\u001b[0m     )\n\u001b[1;32m    163\u001b[0m     \u001b[39mif\u001b[39;00m stream:\n\u001b[1;32m    164\u001b[0m         \u001b[39m# must be an iterator\u001b[39;00m\n\u001b[1;32m    165\u001b[0m         \u001b[39massert\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39misinstance\u001b[39m(response, OpenAIResponse)\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/openai/api_requestor.py:230\u001b[0m, in \u001b[0;36mAPIRequestor.request\u001b[0;34m(self, method, url, params, headers, files, stream, request_id, request_timeout)\u001b[0m\n\u001b[1;32m    209\u001b[0m \u001b[39mdef\u001b[39;00m \u001b[39mrequest\u001b[39m(\n\u001b[1;32m    210\u001b[0m     \u001b[39mself\u001b[39m,\n\u001b[1;32m    211\u001b[0m     method,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    218\u001b[0m     request_timeout: Optional[Union[\u001b[39mfloat\u001b[39m, Tuple[\u001b[39mfloat\u001b[39m, \u001b[39mfloat\u001b[39m]]] \u001b[39m=\u001b[39m \u001b[39mNone\u001b[39;00m,\n\u001b[1;32m    219\u001b[0m ) \u001b[39m-\u001b[39m\u001b[39m>\u001b[39m Tuple[Union[OpenAIResponse, Iterator[OpenAIResponse]], \u001b[39mbool\u001b[39m, \u001b[39mstr\u001b[39m]:\n\u001b[1;32m    220\u001b[0m     result \u001b[39m=\u001b[39m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mrequest_raw(\n\u001b[1;32m    221\u001b[0m         method\u001b[39m.\u001b[39mlower(),\n\u001b[1;32m    222\u001b[0m         url,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    228\u001b[0m         request_timeout\u001b[39m=\u001b[39mrequest_timeout,\n\u001b[1;32m    229\u001b[0m     )\n\u001b[0;32m--> 230\u001b[0m     resp, got_stream \u001b[39m=\u001b[39m \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_interpret_response(result, stream)\n\u001b[1;32m    231\u001b[0m     \u001b[39mreturn\u001b[39;00m resp, got_stream, \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mapi_key\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/openai/api_requestor.py:624\u001b[0m, in \u001b[0;36mAPIRequestor._interpret_response\u001b[0;34m(self, result, stream)\u001b[0m\n\u001b[1;32m    616\u001b[0m     \u001b[39mreturn\u001b[39;00m (\n\u001b[1;32m    617\u001b[0m         \u001b[39mself\u001b[39m\u001b[39m.\u001b[39m_interpret_response_line(\n\u001b[1;32m    618\u001b[0m             line, result\u001b[39m.\u001b[39mstatus_code, result\u001b[39m.\u001b[39mheaders, stream\u001b[39m=\u001b[39m\u001b[39mTrue\u001b[39;00m\n\u001b[1;32m    619\u001b[0m         )\n\u001b[1;32m    620\u001b[0m         \u001b[39mfor\u001b[39;00m line \u001b[39min\u001b[39;00m parse_stream(result\u001b[39m.\u001b[39miter_lines())\n\u001b[1;32m    621\u001b[0m     ), \u001b[39mTrue\u001b[39;00m\n\u001b[1;32m    622\u001b[0m \u001b[39melse\u001b[39;00m:\n\u001b[1;32m    623\u001b[0m     \u001b[39mreturn\u001b[39;00m (\n\u001b[0;32m--> 624\u001b[0m         \u001b[39mself\u001b[39;49m\u001b[39m.\u001b[39;49m_interpret_response_line(\n\u001b[1;32m    625\u001b[0m             result\u001b[39m.\u001b[39;49mcontent\u001b[39m.\u001b[39;49mdecode(\u001b[39m\"\u001b[39;49m\u001b[39mutf-8\u001b[39;49m\u001b[39m\"\u001b[39;49m),\n\u001b[1;32m    626\u001b[0m             result\u001b[39m.\u001b[39;49mstatus_code,\n\u001b[1;32m    627\u001b[0m             result\u001b[39m.\u001b[39;49mheaders,\n\u001b[1;32m    628\u001b[0m             stream\u001b[39m=\u001b[39;49m\u001b[39mFalse\u001b[39;49;00m,\n\u001b[1;32m    629\u001b[0m         ),\n\u001b[1;32m    630\u001b[0m         \u001b[39mFalse\u001b[39;00m,\n\u001b[1;32m    631\u001b[0m     )\n",
      "File \u001b[0;32m/mnt/c/Users/QUAN/Desktop/medical-chatbot/venv/lib/python3.10/site-packages/openai/api_requestor.py:687\u001b[0m, in \u001b[0;36mAPIRequestor._interpret_response_line\u001b[0;34m(self, rbody, rcode, rheaders, stream)\u001b[0m\n\u001b[1;32m    685\u001b[0m stream_error \u001b[39m=\u001b[39m stream \u001b[39mand\u001b[39;00m \u001b[39m\"\u001b[39m\u001b[39merror\u001b[39m\u001b[39m\"\u001b[39m \u001b[39min\u001b[39;00m resp\u001b[39m.\u001b[39mdata\n\u001b[1;32m    686\u001b[0m \u001b[39mif\u001b[39;00m stream_error \u001b[39mor\u001b[39;00m \u001b[39mnot\u001b[39;00m \u001b[39m200\u001b[39m \u001b[39m<\u001b[39m\u001b[39m=\u001b[39m rcode \u001b[39m<\u001b[39m \u001b[39m300\u001b[39m:\n\u001b[0;32m--> 687\u001b[0m     \u001b[39mraise\u001b[39;00m \u001b[39mself\u001b[39m\u001b[39m.\u001b[39mhandle_error_response(\n\u001b[1;32m    688\u001b[0m         rbody, rcode, resp\u001b[39m.\u001b[39mdata, rheaders, stream_error\u001b[39m=\u001b[39mstream_error\n\u001b[1;32m    689\u001b[0m     )\n\u001b[1;32m    690\u001b[0m \u001b[39mreturn\u001b[39;00m resp\n",
      "\u001b[0;31mRateLimitError\u001b[0m: Rate limit reached for 10KTPM-200RPM in organization org-ETbTMTN2JXYOUPDJgxuH2iO6 on tokens per min. Limit: 10000 / min. Please try again in 6ms. Contact us through our help center at help.openai.com if you continue to have issues."
     ]
    }
   ],
   "source": [
    "sample_case = test_cases[0]\n",
    "agent_executor(sample_case)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
